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0929-6646/Copyright ª 2015, ElsevierBackground/Purpose: A risk management plan (RMP) was introduced to monitor the associa-
tion between initiation of antitumor necrosis factor-a (anti-TNF-a) therapy and tuberculosis
(TB) and viral hepatitis infections. The aim of this study was to assess adherence and predic-
tors of laboratory-testing rates among patients treated with anti-TNF-a therapy.
Methods: Data on patients receiving anti-TNF-a therapy between January 1, 2005, and
November 31, 2013, were retrieved from a large medical organization in Taiwan. Newly-
treated patients were categorized into pre- and post-RMP groups. Laboratory testing for TB
and hepatitis B and C was ascertained and the proportion of new users receiving the test
was compared between the pre- and post-RMP groups. Patient characteristics and concomitant
medications used were investigated using multivariate logistic regression to determine the
impact of each factor on laboratory testing.
Results: Among 1128 new users, the initial testing rate of chest X-ray (CXR) for latent TB infec-
tion increased from 60.26% before RMP to 76.38% after RMP implementation; hepatitis B sur-
face antigen (HBsAg) increased from 31.13% to 51.42%; and hepatitis C virus antibody
(HCVAb) increased from 32.2% to 54.10%. CXR was significantly associated with age >60 years,ave no conflicts of interest relevant to this article.
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84 M.-J. Chan et al.higher QuaneCharlson comorbidity index score, psoriasis, and use of prednisolone (7.5 mg/
d). Patients aged 40e60 years and with prednisolone doses of 7.5 mg/d and history of cancer
were more likely to receive HBsAg or HCVAb tests than their counterparts.
Conclusion: The rate of laboratory test monitoring for anti-TNF-a therapy increased after RMP
implementation. A strategy that integrates efforts from patient’s education, health profes-
sion, and regulatory agencies is needed to improve safety screening and access to laboratory
resources for the at-risk group of patients.
Copyright ª 2015, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Tumor necrosis factor (TNF)-a is a proinflammatory cytokine
that causes fever, inflammation, tissue destruction, shock,
and death.1 Reducing the biological activities of TNF-a by
using either neutralizing antibodies (i.e., infliximab, adali-
mumab, and golimumab) or soluble receptors (i.e., eta-
nercept) has been shown to be successful for symptom
reduction and quality of life improvement in chronic inflam-
matory diseases, compared with using disease-modifying
antirheumatic drugs (DMARDs).2e5 The common medications
in this group are methotrexate (MTX), sulfasalazine (SS),
hydroxychloroquine (HQ), and corticosteroids. Patients
treatedwith DMARDs have been associated with an increased
risk of infections than healthy individuals.6,7
Infliximab is the first biologic agent approved by the U.S.
Food and Drug Administration (FDA) for treatment of
Crohn’s disease in 1998; the U.S. FDA approved its use for
rheumatoid arthritis (RA) in 1999. However, infliximab has
not been marketed in Taiwan. Following licensure of anti-
TNF-a agents worldwide, a large volume of postmarketing
evidence from voluntary reports,8 registries,9,10 and claims
database11 analyses revealed an association between
tuberculosis (TB) and other infections and anti-TNF therapy
in patients on long-term DMARDs treatment. In Taiwan,
adalimumab (2003), etanercept (2007), and golimumab
(2011) were licensed for the treatment of juvenile or adult
RA, psoriasis (PS), ankylosing spondylitis (AS), and Crohn’s
disease. The Taiwan FDA (TFDA) alerted the public
regarding the potential risk of hepatitis B virus (HBV)
reactivation in June 2011,12 and risk of TB in August 201113
in patients using anti-TNF-a agents. On April 2, 2012, the
TFDA further announced that the drug manufacturers had
issued a risk management plan (RMP), which aimed to
monitor effectively infectious risks of anti-TNF-a therapy
by adding a physician’s evaluation and prescribing check-
list.14 The TB risk assessment protocol in the RMP recom-
mends that patient’s history, physical examination results,
current immunosuppressive drugs use, and tuberculin skin
test (TST) or chest X-ray (CXR) results should be evaluated
for all patients before administering anti-TNF-a therapy.14
The treatment needs to be discontinued if a patient has
active or latent TB infection (LTBI).
Subsequently, in December 2012, the Taiwan Rheuma-
tology Association (TRA) published a consensus recommen-
dation on screening and management of TB15 and viral
hepatitis16 following the release of RMP by the TFDA. For TB
screening, the TRA specified that CXR should be takenroutinely at baseline and every 6months following anti-TNF-a
therapy.15 Although TST and interferon-gamma release assay
are considered to detect LTBI, these tests are not sufficiently
accurate and have known limitations for diagnosing LTBI in
immunosuppressive patients.15 Therefore, clinical assess-
ments and CXR screening remain primary tools to detect
early, active LBTIs, or LTBIs in patients due to initiation of
anti-TNF-a therapy. For viral hepatitis screening, RMP and
TRA consensus recommendations are agreed on screening for
risk factors for hepatitis B infection before and every 3e6
months after initiation of anti-TNF-a therapy.14,16
TB, HBV and hepatitis C virus (HCV) infections continue
to be the major diseases in Taiwan. In Taiwan, there were
12,338 incident TB cases (53/100,000 population)17 and 626
deaths due to TB in 2012.18 Although the burden of HBV
reduced in young people after the launch of universal HBV
vaccination strategy,19 HBV/HCV co-infection remained the
leading cause of death (4975 deaths) in 2012.18 For these
reasons, there is a need to increase awareness about anti-
TNF-a therapy-related infections and to regularly monitor
patients who are at high risk of infections. The aim of this
study was to measure the differences in laboratory-testing
frequency among patients newly treated with an anti-TNF-
a agent in practice before and after the RMP implementa-
tion period. We also investigated whether the testing fre-
quency was associated with the pattern of concomitant
medications use and baseline clinical conditions.Methods
Study setting and data set
Chang Gung Medical Foundation (CGMF) is a group-based
hospital, with in-house information technology personnel to
maintain standardized data on all-patients’ encounters and
electronic health-care data, including patients’ medical
records, pharmacy dispensing records, and laboratory test
results, and the medical procedures the patients received.
According to statistics published in 2013,20 CGMF provided
approximately 11% of the Taiwan National Health Insurance
(NHI) program-reimbursed health care services. The Taiwan
NHI program is a compulsory, nationwide health insurance
program, which includes >95% of contracted hospitals in
Taiwan and 99% of the entire 23 million individuals enrolled
in the program.21 CGMF offers a large, centralized database
from the hospitals located from the Northern to the
Southern regions of Taiwan (i.e., Keelung, Taipei, Linkou,
Compliance to anti-TNF-a therapy of risk management plan 85Chaiyi, and Kaohsiung), therefore, the study participants
are considered generalizable to the general population.
The study was approved by the Institutional Review Board
in the CGMF.
Patients
Eligible participants were patients who had at least one
prescription for any anti-TNF-a agent between January 1,
2005, and November 30, 2013, including etanercept
(Enbrel), adalimumab (Humira), and golimumab (SIMPONI).
Only patients who received anti-TNF-a agents for the first
time (index therapy) between January 1, 2010, and
November 30, 2013, were included in the analysis, based on
the pharmacy dispensing date. The patients were divided
into two groups depending on the timing of their index
therapy before or after January 1, 2012. Because the
TFDA’s risk management strategy for communicating and
preventing risk of medicines is new to our health-care
system, we did not identify specific changes in prescribing
patterns of anti-TNF-a therapy within and beyond the
period between June 2011 and September 2012. The risk-
communication efforts were carried out by the TFDA and
TRA. We hypothesized that the effect of risk communica-
tions in the early adoption period (June 2011eApril 2012) is
limited on screening frequency in the study setting.22
Furthermore, differences observed between the pre- and
post-RMP periods were assumed to be due to the combined
risk-communications efforts.
Use of concomitant medications
Risk of developing TB and other infections increased in
patients treated with DMARDs6,7; therefore, assessing the
frequency of safety monitoring for infections among pa-
tients receiving anti-TNF-a therapy should consider a
combination of DMARDs and glucocorticoids (GCs) with anti-
TNF-a therapy. Conventional DMARDs included MTX, SS, HQ,
and leflunomide; nonconventional DMARDs included
azathioprine, mycophenolic acid, cyclophosphamide, and
penicillamine. The nonanti-TNF-a biological regimens
included tocilizumab, ustekinumab, rituximab, and abata-
cept. In general, the first-line treatment for patients with
active disease was monotherapy with MTX or other con-
ventional DMARDs if MTX was contraindicated. When pa-
tients did not reach the therapeutic target, dual
conventional DMARDs were considered with or without
combination with oral GCs or biologicals agents.23,24
Concomitant use of DMARDs was identified from phar-
macy dispensing records and classified as no DMARDs; MTX
alone; single conventional DMARD (excluding MTX); dual
conventional DMARDs (MTX þ HQ, MTX þ SS, HQ þ SS, and
MTX þ leflunomide); dual nonconventional DMARDs (any 2
of the 4 nonconventional DMARDs, namely, azathioprine,
mycophenolic acid, cyclophosphamide, and penicillamine);
triple DMARDs; and other types of combinations. Following
the treatment guidelines,23 patterns of concomitant use of
DMARDs and GCs were used as proxies to indicate the
severity of inflammatory disease at the time of anti-TNF-a
therapy initiation (index date). Patients were classified to
be in a mild disease state (less risk of infection) if they weretreated with monotherapy or dual combination of conven-
tional DMARD therapy; or in a severe disease state (higher
risk of infection) if they underwent dual therapy with
nonconventional DMARDs, triple DMARD therapy, or other
types of combinations.
Concomitant use of oral GCs was also identified at the
index date as no use, low dose, or high dose. According to
the dosage and day’s supply of specific GCs, which were
obtained from the prescription order, low dose is referred
to a dose of 7.5 mg/d of prednisolone or equivalent, and
high dose is defined as a dose of 7.5 mg/d of prednisolone
or equivalent. In addition, we also assessed study partici-
pants with or without injection of GCs during the study
period (index date  6 months).
Adherence of RMP to anti-TNF-a therapy
To evaluate the adherence to RMP recommendations for in-
fectious risk monitoring, safety-monitoring rate was defined
as the proportion of new users of anti-TNF-a therapy who
received a laboratory test for TB, HBV, and HCV infections
during the treatment initiation period (index date  6
months) and then every 3 months [liver function tests (LFTs)]
and 6 months (CXR) for those patients who continued to
receive the therapy for 6 months (with 30-day permissible
gap). Appendix Figure 1A and 1B show the study time frame
for safety monitoring of anti-TNF-a therapy.
For TB evaluation, the TST and CXR were recommended
prior to the start of therapy. Acid-fast stain and TB poly-
merase chain reaction were used to confirm suspected
cases of TB. Initial monitoring for HBV infection was ach-
ieved by measuring hepatitis B surface antigen (HBsAg) to
identify carriers, hepatitis B core antibody (HBcAb), hepa-
titis B core immunoglobulin M (anti-HBcIgM), hepatitis B
surface antibody (HBsAb), hepatitis B DNA, and hepatitis Be
antigen. The test for HCV antibody (HCVAb) was carried out
for monitoring HCV infection. LFTs included evaluation of
aspartate aminotransferase, alanine aminotransferase
(ALT), total/direct bilirubin, prothrombin time, a-fetopro-
tein, and abdominal ultrasound. Periodic safety monitoring
following treatment initiation was every 6 months for CXR
and every 3 months for ALT.
To address the issue of unequal observation duration, a
subgroup analysis was performed for a group of participants
who initiated therapy in the pre-RMP period and persisted
with therapy with a 30-day permissible gap for at least 6
months before and after January 1, 2012 (Appendix Figure
1C). Safety-monitoring frequency for CXR and LFTs (ALT)
was compared before and after January 1, 2012, to explore
the effects of the RMP within the same group of patients.
Covariates
Covariates considered important were patients’ de-
mographic characteristics, baseline comorbid conditions,
and infectious risk at the therapy index date. Baseline in-
fectious risk data including the history of LTBI (ICD-9-CM,
795.5), TB (ICD-9-CM, 010-018.x), late effect of TB (ICD-9-
CM, 137.x), hepatitis carrier (ICD-9-CM, V026), viral hepa-
titis (ICD-9-CM, 070), chronic liver disease except alcoholic
related (ICD-9-CM, 571-573.x and excluding ICD-9-CM,
86 M.-J. Chan et al.571.0-571.3), and malignancy (ICD-9-CM, 140-239.x) were
extracted within 1 year before or 30 days after the index
date from hospitalization, and from outpatient records.
The QuaneCharlson comorbidity index (QuaneCCI) score25
was used to quantify the burden of comorbid conditions
from hospitalization and outpatient records during the 1
year before or 30 days after treatment initiation. Pre-
scribing patterns and use of anti-TNF-a therapy with
DMARDs and GCs were assessed.
Statistical analysis
Descriptive analysis was performed using means and stan-
dard deviations for continuous variables, and numbers and
percentage for categorical variables. Statistical tests of
significance for differences between the pre- and post-RMP
groups used Pearson Chi-square test for dichotomous vari-
ables and t test for continuous variables. Multivariate lo-
gistic regression was performed to examine the effect of
RMP implementation on safety-monitoring frequency while
controlling for demographic characteristics and clinical
conditions. Results were expressed as adjusted odds ratioTable 1 Characteristics of study cohort at baseline.
Characteristics Pre-RMP (n Z
Age at therapy initiation 48.3  16.4
Distribution of age (y)
20 30 (5.7)
21e30 57 (10.7)
31e40 91 (17.1)
41e50 97 (18.3)
51e60 132 (24.9)
>60 124 (23.4)
Women 299 (56.6)
Underlying inflammatory disease
Rheumatoid arthritis 290 (54.6)
Ankylosing spondylitis 115 (21.7)
Psoriasis 124 (23.4)
Crohn’s disease 2 (0.4)
Off-labeled indicationsa 47 (8.9)
Multiple diseases state 93 (8.7)
Baseline infectious risk
Latent tuberculosis 12 (2.26)
Tuberculosis 11 (2.07)
Viral hepatitis 11 (2.07)
Chronic liver disease (nonalcoholic) 86 (16.20)
Cancer 52 (9.79)
QuaneCharlson comorbidity score 1.2  1.1
Physician-initiated anti-TNF-a regimen
Rheumatology 395 (74.39)
Dermatology 96 (18.08)
Gastroenterology 4 (0.75)
Pediatrics 23 (4.33)
Others 13 (2.45)
Data are presented as mean  SD or n (%).
Baseline infectious risk and QuaneCharlson comorbidity conditions w
RMP Z risk management plan; SD Z standard deviations; TNF Z tum
a Anti-TNF-a-agent-labeled indications: rheumatoid arthritis in eithe
disease.(OR) with 95% confidence intervals (CIs). All data processing
and analyses were conducted using SAS Enterprise Guide
version 4.2 (SAS Inc., Cary, NC, USA).
Results
We identified 1128 (57.9% female) new users of anti-TNF-a
therapy, with an average age at therapy initiation of
48.3  16.0 years. Patients with RA accounted for 55%,
followed by PS and AS (21.4% and 22.7%, respectively) and
15.2% of them had at least two inflammatory diseases. The
most common infectious risk was nonalcoholic chronic liver
disease (15.8%). Most new users of anti-TNF-a therapy were
treated by rheumatologists (74.7%), followed by dermatol-
ogists (17.9%); pediatricians accounted for 3.9%. The pa-
tients’ characteristics at baseline between the pre-RMP and
post-RMP groups were similar (Table 1).
Patterns of medication use
Etanercept was the most common index therapy (54%) in
the study cohort. Golimumab became available in 2012,531) Post-RMP (n Z 597) p
48.3  15.5 0.340
27 (4.5) 0.6250
57 (9.6)
97 (16.3)
126 (21.1)
167 (28.0)
132 (20.6)
354 (59.3) 0.979
338 (56.6) 0.538
126 (21.1) 0.879
132 (22.1) 0.670
4 (0.7) 0.690
40 (6.7) 0.215
79 (6.5) 0.215
16 (2.68) 0.794
11 (1.84) 0.951
17 (2.85) 0.519
92 (15.41) 0.780
66 (11.06) 0.553
1.2  1.1 0.744
448 (75.04) 0.854
106 (17.76) 0.949
2 (0.34) 0.580
21 (3.52) 0.582
20 (3.35) 0.471
ere assessed within 1 y before or 30 d after the index date.
or necrosis factor.
r juvenile or adult, psoriasis, ankylosing spondylitis, and Crohn’s
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to golimumab in the post-RMP group. The majority of
patients received anti-TNF-a monotherapy and only 23
(approximately 2%) received a second anti-TNF-a agent
within 6 months after index therapy (Appendix Table 1).
More new users (66.48%) in the pre-RMP group received
GCs compared with those in the post-RMP group (64.82%).
By contrast, there were more new users who had never
received a biologic product other than anti-TNF-a ther-
apy in the post-RMP group (1.17%) than those in the
pre-RMP group (0.19%). There was no significant differ-
ence between the groups in the use of prior therapy
(Appendix Table 1).
Patterns of concomitant use of DMARD and GCs with
anti-TNF-a therapy between the pre- and post-RMP groups
are summarized in Table 2. Dual therapy with conventional
DMARDs was the most common form of concomitant medi-
cation (21.90%), and half of new users had no DMARDs at the
time of starting anti-TNF-a therapy. No significant differ-
ence between concomitant uses of DMARDs and GCs and
severity of disease was observed between the groups.
However, the proportion of patients with high doses of GCs
was higher in the pre-RMP group (19.59%) compared with
those in the post-RMP group (17.92%; Table 2). The use of
GC injection was also significantly higher in the pre-RMP
group than in the post-RMP group (21.9% vs. 15.6%,
p Z 0.009).Table 2 Patterns of concomitant medication use.
Concomitant medications Pre-RM
Use of DMARD *
No DMARDs 160 (3
MTX alone 37 (6
Single conventional DMARD (no MTX) 80 (1
Combination of two conventional DMARDsa 108 (2
Combination of two nonconventional DMARDsb 38 (7
Combination of three DMARDs 97 (1
Other combinations 11 (2
Disease severityc
Mild disease 108 (2
Severe diseases 423 (7
Use of oral GCsd
No oral GC 268 (5
<7.5 mg/d 159 (2
7.5 mg/d 104 (1
Use of injection GCse 116 (2
Data are presented as n (%).
* Concomitant use of DMARDs and GCs was assessed at the index date
DMARD Z disease-modifying antirheumatic drug; GC Z glucocorticoi
management plan; SS Z sulfasalazine; TNF Z tumor necrosis factor.
a Combination of dual conventional DMARDs: MTX þ SS, MTX þ HQ,
b Combination of dual nonconventional DMARDs: any combinatio
penicillamine.
c Disease severity: mild disease states Z no DMARDs, mono or dual
therapy with nonconventional DMARDs, triple therapy with DMARDs, a
d Low dose: <7.5 mg/d prednisolone or equivalent dose; high dose:
e Use of injection form of GCs was assessed in the period of the indAdherence to RMP recommendations for infection
monitoring
Table 3 shows the initial safety-monitoring rates at treat-
ment initiation between the pre- and post-RMP groups.
There was a significant increase in screening rate for TB
(CXR) from 60.3% in the pre-RMP group to 76.4% in the post-
RMP group (p < 0.001). The screening rate significantly
increased for HBV infection at baseline from 30.1% in the
pre-RMP group to 51.4% in the post-RMP group for HBsAg
(p < 0.001), from 7.9% to 39.9% for HBcAb (p < 0.001), and
from 5.5% to 38.2% for HBsAb (p < 0.001). The screening
rate for HCV (HCVAb) also significantly increased from
32.2% in the pre-RMP group to 54.1% in the post-RMP group
(p < 0.001). However, no significant difference in liver
function monitoring at baseline was observed.
The periodic monitoring rate in the follow-up period
among patients who persistently received anti-TNF-a
therapy for >6 months revealed an increased trend over
time for CXR (Figure 1A). The rates of CXR monitoring every
6 months increased from 19.2% in 2010 to 45% in 2013,
whereas the rate of LFTs remained in the range of
72.3e85.2% during the study period (Figure 1B).
Of 531 patients who initiated therapy in the pre-RMP
period, 136 (25.6%) continued therapy and were eligible for
the subgroup analysis. The CXR rate increased from 28.7%
before January 1, 2012, to 36.8%afterward,due toaddition ofP (n Z 531) Post-RMP (n Z 597) p
0.13) 179 (29.98) >0.99
.97) 38 (6.37) 0.775
5.07) 84 (14.07) 0.697
0.34) 139 (23.28) 0.262
.16) 34 (5.70) 0.379
8.27) 110 (18.43) >0.99
.07) 13 (2.18) >0.99
0.262
0.34) 139 (23.28)
9.66) 458 (76.72)
0.953
0.47) 293 (49.08)
9.94) 197 (33.00)
9.59) 107 (17.92)
1.85) 93 (15.58) 0.009
for starting anti-TNF-a therapy.
d; HQ Z hydroxychloroquine; MTX Z methotrexate; RMP Z risk
MTX þ leflunomide, and HQ þ SS.
n of azathioprine, mycophenolic acid, cyclophosphamide, and
therapy with conventional DMARDs; severe disease state Z dual
nd other types of combinations.
7.5 mg/d prednisolone or equivalent dose.
ex date 6 mo.
Table 3 Initial safety-monitoring rate between the pre- and post-RMP periods.
Item of safety monitoring Pre-RMP (N Z 531) Post-RMP (N Z 597) p
Tuberculosis relevant
Latent TB
Tuberculin skin test 73 (13.75) 76 (12.73) 0.678
Chest X-ray 320 (60.26) 456 (76.38) <0.001
Suspected TB infection
Acid-fast stain 4 (0.75) 3 (0.50) 0.713
TB PCR 5 (0.94) 5 (0.84) >0.99
Viral hepatitis relevant
Hepatitis B virus
HBsAg 160 (30.13) 307 (51.42) <0.001
HBsAb 29 (5.46) 228 (38.19) <0.001
Anti-HBcIgM 8 (1.51) 12 (2.01) 0.679
HBcAb 42 (7.91) 238 (39.87) <0.001
HBeAg 17 (3.20) 23 (4.19) 0.474
Hepatitis C virus
HCVAb 171 (32.20) 323 (54.10) <0.001
Liver function test
Aspartate aminotransferase 367 (69.11) 410 (68.68) 0.925
Alanine aminotransferase 495 (93.22) 559 (93.63) 0.873
Total bilirubin 149 (28.06) 165 (27.64) 0.927
Direct bilirubin 75 (14.12) 66 (11.06) 0.143
Prothrombin time 94 (17.70) 101 (16.92) 0.788
Alpha-feto protein 54 (10.17) 72 (12.06) 0.362
Abdominal ultrasound 89 (16.76) 112 (18.76) 0.425
HBcAbZ hepatitis B core antibody; HBcIgMZ hepatitis B core immunoglobulin M; HBeAgZ hepatitis Be antigen; HBsAbZ hepatitis B
surface antibody; HBsAg Z hepatitis B surface antigen; HCVAb Z hepatitis C virus antibody; PCR Z polymerase chain reaction;
RMP Z risk management plan; TB Z tuberculosis.
88 M.-J. Chan et al.23.5% of patients who did not undergo testing before treat-
ment and received a test after January 1, 2012. By contrast,
the ALT-testing rate showed only a slight decrease (Figure 2).Key factors associated with safety monitoring at
starting therapy
Table 4 summarizes the adjusted odds of receiving initial
safety monitoring in relation to patient characteristics. The
likelihood of receiving CXR monitoring was significantly
higher among patients who initiated therapy in the post-
RMP period compared with those who initiated the ther-
apy in the pre-RMP period (OR 2.31, 95% CI 1.77e3.01).
Other significant factors associated with CXR monitoring
were patients aged >60 years (OR 1.53, 95% CI 1.02e2.31),
with a higher QuaneCCI score (OR 1.34, 95% CI 1.15e1.56),
indication of psoriasis (OR 2.14, 95% CI 1.18e3.87), and
those who had 7.5 mg/d dose of prednisolone or equiva-
lent at the time of starting anti-TNF-a therapy (OR 1.54,
95% CI 1.01e2.37).
The likelihood of receiving HBV screening (HBsAg) was
greater if patients started anti-TNF-a therapy in the post-
RMP period (OR 2.73, 95% CI 2.10e3.54), or were aged
41e50 years (OR 1.75, 95% CI 1.21e2.53) or 51e60 years
(OR 1.59, 95% CI 1.11e2.27). Patients who received a high
dose (7.5 mg/d) of prednisolone or equivalent drug (OR
1.51, 95% CI 1.01e2.25) and had a medical history of cancer
(OR 1.61, 95% CI 1.05e2.47) had a higher relative likelihoodof receiving HBV monitoring. The odds of receiving HBsAg
test were significantly lower in patients treated with more
than two labeled indications (OR 0.40, 95% CI 0.20e0.78),
RA (OR 0.20, 95% CI 0.11e0.35), and AS (OR 0.41, 95% CI
0.23e0.72) than off-labeled indications.
Similar results were found when considering HCV
(HCVAb) monitoring. Patients who initiated anti-TNF-a
therapy in the post-RMP period (OR 2.70, 95% CI
2.09e3.49), aged 41e50 years (OR 1.79, 95% CI 1.24e2.58),
with a high dose of GCs (OR 1.61, 95% CI 1.08e2.39) had a
higher relative likelihood of receiving HCV monitoring.
Compared with patients treated with off-labeled in-
dications, the odds of receiving HCVAb test were lower, if
patients were treated with at least two labeled indications
(OR 0.41, 95% CI 0.21e0.80), and had RA (OR 0.20, 95% CI
0.11e0.35) and AS (OR 0.50, 95% CI 0.28e0.88).Discussion
Government agencies in many countries have tried through
a variety of risk-communication tools to reinforce the
importance of monitoring infections and other risks asso-
ciated with anti-TNF biological therapy. This study revealed
that adherence to recommended laboratory tests increased
after RMP implementation among those receiving anti-TNF-
a therapy. These tests (CXR, HBsAg, HCVAb, and LFTs) have
a propensity for early detection of the risk of infection
associated with anti-TNF-a therapy.
Figure 1 Periodic safety-monitoring patterns for (A) TB and (B) viral hepatitis among anti-TNF-a users. HZ every half year or 6
months; Q Z every quarter or 3 months; TB Z tuberculosis; TNF Z tumor necrosis factor-a.
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pears to be comparable with the responses to a variety of
interventions evaluated in some recent studies assessing the
impact of risk-communication efforts in patients using anti-
TNF therapy.22,26 Hanson et al26 reported that the safety-
monitoring rate doubled (from 31% before to 60% after the
intervention) through a preorder checklist for individual
patients who were preparing to start therapy with anti-TNF-
a agents and other biologic products. The compliance was
measured by the completion rates for all four laboratory
tests (TB, HBsAg, liver function, and complete blood counts)
prior to initiating therapy, and compared before (August
2011eJanuary 2012) and after (February 2012eJuly 2012)the implementation of the hospitalwide intervention. Using
an administrative claims database, Shatin et al22 observed
that the rate of TST among infliximab users doubled from
15.4% before (October 2000) to 30.9% after implementing
multimodal risk-communication efforts (June 2002).
Our study showed a relatively low TST rate (13.2%) for TB
screening compared with previous studies in other coun-
tries.22 Although TST is recommended by government-
initiated RMP and expert committees, there are several
issues concerning the validity of its result. For instance, the
nationwide neonatal Bacillus CalmetteeGue´rin vaccination
policy has been promoted well in Taiwan and prevalence of
nontuberculosis Mycobacterium infection has increased in
Figure 2 Safety-monitoring rate before and after RMP among
a subgroup of patients (n Z 136). Patients (n Z 136) included
in the subgroup analysis were those who started anti-TNF
therapy before January 1, 2012, and persisted with therapy
at least 6 months before and after January 1, 2012.
ALT Z alanine aminotransferase; RMP Z risk management
plan; TNF Z tumor necrosis factor.
90 M.-J. Chan et al.recent years.27 Both these findings can lead to false-
positive TST results, and some patients with anergy (im-
mune tolerance) may have false-negative TST results.28
Subsequently, physicians have raised concerns about the
value and effectiveness of TST for TB screening, which had
led to its low rate of use. Instead of TST being the first
choice for TB screening, CXR has become the most common
test (68.79%) to rule out infections in medical practice. For
HBV infection, the rate of HBsAg testing increased, and
testing for HBcAb and HBsAb increased fivefold after RMP
implementation, which indicated a significant impact of
risk-communication efforts.
One of the important strengths of our study was that we
identified key factors associated with adherence of safety
monitoring, which enabled us to understand better the bar-
riers of implementing RMP in ordinary practice settings. Our
results revealed that patient age at the therapy index date
had a differential effect on TB and viral hepatitis testing,
although the significance did not hold across all age groups.
These findings were consistent with treatment patterns
retrieved from the Taiwan NHI research database for the
same study population, which included prescribing anti-TB
treatmentmainly for patients aged>60 years,29 and anti-HBV
and anti-HCV therapy for patients aged 40e60 years.30 Not
surprisingly, concomitant use of high-dose prednisolone or
equivalent (7.5 mg/d) in patients receiving immunosup-
pression increased safety monitoring by 50%.
The current government-initiated guidelines do not
define laboratory monitoring tests for specific indications
among anti-TNF-a therapy users. Except for rheumatolo-
gists, currently, there is no consensus or guidelinespublished for dermatologists and other specialty of physi-
cians. The study results found that adherence to laboratory
testing for treatment-naı¨ve patients differed by in-
dications. The likelihood of receiving TB screening
appeared to be higher in most patients with labeled in-
dications than with off-labeled indications (except AS and
Crohn’s disease). For viral hepatitis, by contrast, all
treatment-naı¨ve patients with labeled indications had a
lower likelihood of receiving either HBsAg or HCVAb
screening. Although the frequency of off-labeled in-
dications used for anti-TNF-a therapy (n Z 87, 7.7%)
revealed a nonstatistical significance between the pre- and
post-RMP groups (p Z 0.215), it makes patients unlikely to
receive recommended laboratory tests. Low frequency of
ordering tests possibly can be explained by the fact that
physicians prescribed the study medications for younger
and less immunocompromised patients, or providers are not
inflammatory diseases specialists (nZ 33 in department of
others) in the study setting. These results suggested that
variations in indication-related factors (physician’s spe-
cialty, knowledge, and attitudes) may not be the only
sources causing differential adherence to RMP’s recom-
mendations. Relatively low rate of serology and virology
testing in all patients with labeled indications may suggest
a greater impact of unmeasured barrier in the current
practice setting (e.g., screening tests are not reimbursed,
decision between prophylactic antiviral therapy and
routine serologic screening remains uncertain). Despite
health-care provider’s knowledge about the key risks and
safe use of the therapy, an understanding of how health
system factors influence screening behavior in practice
should help improve screening rate and effectively manage
possible adverse events associated with the use of anti-TNF
therapy.
This study had some limitations. First, specific labora-
tory monitoring was not mandated; therefore, physician
judgments through physical examination and history taking
may have led to the testing rate being underestimated. A
previous study showed that rheumatologists mainly relied
on clinical assessments (92%), including patients’ history
and physical examination, hepatic enzymes (69%), and
complete blood count (77%), and less than half of rheu-
matologists ordered CXR screening when initiating DMARD
therapy.31 Therefore, the rate of laboratory testing in this
study may not be fully generalizable to physicians’ expe-
rience, knowledge, and behavior outside the study setting.
Second, patient compliance was not measured in this
study. There are no patient educational materials or
leaflets about the potential infection risk of anti-TNF
therapy in the study setting. We could not ascertain
whether not taking a laboratory test was due to patient
preference. The study findings may not be generalizable to
other populations with different patient characteristics.
Furthermore, we cannot rule out possible unmeasured
confounders, such as free laboratory tests for TB and viral
hepatitis performed outside of the study setting; in addi-
tion, physicians may be worried that some laboratory tests
are not reimbursed by the National Insurance Program,
which could lead to underestimation of safety monitoring
in this study.
In conclusion, the level of compliance with laboratory
monitoring guidelines for infectious risk improved among
Table 4 Factors associated with safety monitoring.
Variable Chest X-ray HBsAg HCV Ab
Odds ratio (95% CI)a p Odds ratio (95% CI)a p Odds ratio (95% CI)a p
Risk management plan
Before Ref Ref Ref
After 2.31 (1.77e3.01) <0.001 2.73 (2.10e3.54) <0.001 2.70 (2.09e3.49) <0.001
Sex
Women Ref Ref Ref
Men 1.09 (0.80e1.49) 0.584 0.89 (0.66e1.20) 0.441 0.77 (0.58e1.04) 0.090
Age group (y)
40 Ref Ref Ref
41e50 1.43 (0.97e2.11) 0.068 1.75 (1.21e2.53) 0.003 1.79 (1.24e2.58) 0.002
51e60 1.21 (0.83e1.75) 0.322 1.59 (1.11e2.27) 0.012 1.38 (0.97e1.98) 0.073
>60 1.53 (1.02e2.31) 0.040 1.13 (0.76e1.69) 0.544 1.20 (0.81e1.77) 0.367
QuaneCCI 1.34 (1.15e1.56) <0.001 0.90 (0.79e1.01) 0.075 0.92 (0.82e1.03) 0.162
Variable Chest X-ray HBsAg HCV Ab
Odds ratio (95% CI)a p Odds ratio (95% CI)a p Odds ratio (95% CI)a p
Underlying disease
Off-labeled indicationsb Ref Ref Ref
Rheumatoid arthritis 1.02 (0.58e1.82) 0.935 0.20 (0.11e0.35) <0.001 0.20 (0.11e0.35) <0.001
Ankylosing spondylitis 0.94 (0.53e1.69) 0.843 0.41 (0.23e0.72) 0.002 0.50 (0.28e0.88) 0.016
Psoriasis 2.14 (1.18e3.87) 0.012 0.63 (0.37e1.10) 0.106 0.62 (0.36e1.09) 0.095
Crohn’s disease 0.36 (0.02e6.20) 0.485 d d 0.36 (0.02e6.31) 0.487
Two or more labeled indications 1.47 (0.72e2.97) 0.289 0.40 (0.20e0.78) 0.007 0.41 (0.21e0.80) 0.009
Disease severityc
Mild disease states Ref Ref Ref
Severe disease states 1.05 (0.73e1.51) 0.788 0.86 (0.61e1.21) 0.381 0.88 (0.63e1.24) 0.463
Use of oral GCsd
No oral GC Ref Ref Ref
<7.5 mg/d 0.86 (0.61e1.22) 0.403 1.16 (0.83e1.61) 0.389 1.38 (0.99e1.92) 0.056
7.5 mg/d 1.54 (1.01e2.37) 0.046 1.51 (1.01e2.25) 0.044 1.61 (1.08e2.39) 0.018
Baseline infectious risk
Latent TB 2.61 (0.85e7.99) 0.094 0.60 (0.25e1.45) 0.256 0.39 (0.16e0.98) 0.046
Tuberculosis 3.53 (0.77e16.18) 0.105 1.40 (0.53e3.72) 0.502 1.52 (0.58e4.00) 0.398
Viral hepatitis 1.34 (0.45e3.97) 0.600 0.57 (0.21e1.52) 0.259 0.66 (0.26e1.69) 0.385
Viral hepatitis carrier 0.44 (0.09e2.25) 0.322 3.28 (0.48e22.44) 0.227 3.09 (0.48e19.99) 0.235
Chronic liver disease 0.55 (0.36e0.83) 0.005 0.96 (0.65e1.42) 0.827 0.89 (0.61e1.31) 0.562
Cancer 1.28 (0.78e2.08) 0.327 1.61 (1.05e2.47) 0.029 1.39 (0.91e2.12) 0.131
CCI Z Charlson comorbidity index; CI Z confidence interval; DMARDs Z disease-modifying antirheumatic drug; GC Z glucocorticoid;
HBsAgZ hepatitis B surface antigen hepatitis B surface antigen; HCVZ hepatitis C virus; RAZ rheumatoid arthritis; TBZ tuberculosis;
TNF Z tumor necrosis factor.
a Adjusted for all variables listed in the table.
b Labeled indications for starting anti-TNF-a therapy included juvenile or adult RA, psoriasis, ankylosing spondylitis, psoriasis, and
Crohn’s disease.
c Disease severity was based on the use of DMARDs at the study index date. Mild disease states refer to mono or dual therapy with
conventional DMARDs; severe disease states refer to dual therapy with nonconventional DMARDs, triple therapy with DMARDs, and other
types of combinations.
d Low dose: <7.5 mg/d prednisolone or equivalent dose; high dose: 7.5 mg/d prednisolone or equivalent dose.
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in 2012. The decision to initiate or continue anti-TNF-a
treatment should balance the risks of treating the under-
lying inflammatory diseases with DMARDs and GCs against
the additional infectious risks associated with anti-TNF-a
regimens. There is a need for large, well-designed studies
to examine the competitive risk of anti-TNF-a therapy and
other treatment choices for this immunocompromised
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Appendix 1. Time frame for safety-monitoring analysis.
(A). Initial monitoring period. Those with any safety monitoring during 6 months before or after the index date were regarded as
completers. No matter what point in time (A or B), there were no differences. (B) Periodic monitoring period. We examined
whether the persistent TNF-a new users had the safety-monitoring record every 3 months or 6 months. Times A, B, and C were
attributed to different periodic safety-monitoring rates. (C) A subgroup analysis for comparison (before vs. after RMP imple-
mentation). The testing rate of chest X-ray and ALT between 6 months before and after January 1, 2012, among the subgroup of
patients described. ALT [ alanine aminotransferase; RMP [ risk management plan; TNF [ tumor necrosis factor.
Appendix 2. Patterns of anti-TNF-a therapy use.
Medications Pre-RMP
(n Z 531)
Post-RMP
(n Z 597)
p
Anti-TNF-a therapy
Only one anti-TNF-a
agent received
520
(97.93)
585 (97.99) >0.99
Etanercept 321
(60.45)
281 (47.07) <0.001
Adalimumab 199
(37.48)
215 (36.01) 0.647
Golimumab 0 89 (14.91) <0.001
Two anti-TNF-a agents
received
11 (2.07) 12 (2.01) >0.99
Etanercept þ adalimumab 11 (2.07) 9 (1.51) 0.217
Etanercept þ golimumab 0 1 (0.71) 0.217
Adalimumab þ golimumab 0 2 (0.34) 0.478
Prior therapya
Nonanti-TNF-a biologic
therapyb
1 (0.19) 7 (1.17) 0.073
Glucocorticoids 353
(66.48)
387 (64.82) 0.602
Data are presented as n (%).
Patterns of anti-TNF-a therapy use were assessed 6 months after the index date.
RMP Z risk management plan; TNF Z tumor necrosis factor.
a Prior therapy was assessed within 1 year before the index date.
b Nonanti-TNF-a biologic therapy included abatacept, tocilizumab, ustekinumab, and rituximab.
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